Drug Profile
CPI 100
Alternative Names: CPI-100Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Coordination Pharmaceuticals
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 21 Jun 2022 Coordination Pharmaceuticals completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03781362)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)